We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Engagements

MYBOARD is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Insights

MYinSIGHTS provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

MYConference Targeted Reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Nivolumab May Restore T-Cell Fitness Following CAR T-Cell Therapy in Patients With Multiple Myeloma

Source: Pharmacy Times articles Real-time profiling of T-cell activation states in non-CAR T-cells may help guide treatment decisions. Read More

Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma

Source: Myeloma : nature.com subject feeds Post Content Read More

Long-Term Follow-Up Data from the CASSIOPEIA Trial Show Continued MRD, PFS Benefit in Multiple Myeloma

Source: Pharmacy Times articles Adding daratumumab improved minimal residual disease (MRD) negativity rates, leading to superior progression-free survival (PFS). Read More

Recent Publications

Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma: A Systematic Review and Meta-Analysis

Cancer Rep (Hoboken). 2025 Apr;8(4):e70171. doi: 10.1002/cnr2.70171. ABSTRACT BACKGROUND: The...

Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma

Mol Ther. 2025 Mar 31:S1525-0016(25)00222-9. doi: 10.1016/j.ymthe.2025.03.048. Online ahead of...

Prognostic and clinicopathological value of the controlling nutritional status score in patients with multiple myeloma: a meta-analysis

Front Oncol. 2025 Mar 18;15:1517223. doi: 10.3389/fonc.2025.1517223. eCollection 2025. ABSTRACT...

Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review

Front Oncol. 2025 Mar 12;15:1550644. doi: 10.3389/fonc.2025.1550644. eCollection 2025. ABSTRACT...

Email

info@myeloma360.com